Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.74 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.74 |
| ▸ | DPP4 | P27487 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.74 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.74 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.74 |
| ▸ | GAPDH | P04406 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.74 |
| ▸ | STAT6 | P42226 | 1/20 | 0.74 |
| ▸ | PI4KA | P42356 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.74 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.74 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.74 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.74 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15926827 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15338536 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15338502 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL29936504 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL15788449 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL384075 | 1.00 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| Trifluoroacetic Acid SCHEMBL4666841 | 0.91 | ADORA1 (0.65) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL24371423 | 0.91 | ADORA3 (0.76) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL3447141 | 0.91 | ADORA1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL4581742 | 0.90 | P2RY1 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4115 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739794-A1 | METHODS, COMPOSITONS, AND SYSTEMS FOR ANALYTE DETECTION | Stellaromics, Inc. (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4684016-A2 | METHODS AND MATERIALS FOR TREATING CANCER | The Regents of the University of California (US) | 2026-01-28 | — | — | EP | claimed |
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| CN-119907691-A | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions and therapeutic uses | 厦门甘宝利生物医药有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-119789859-A | Treatment of non-alcoholic fatty liver disease | 箭头药业股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2025036956-A1 | NON-SYSTEMIC MRNA ADMINISTRATION | ETHRIS GMBH (DE) | 2025-02-20 | — | — | WO | claimed |
| CN-119432957-A | Method for preparing RNA by in vitro transcription and application thereof | 启辰生生物科技(珠海)有限公司 | 2025-02-14 | — | — | CN | claimed |
| WO-2025014828-A1 | METHODS, COMPOSITONS, AND SYSTEMS FOR ANALYTE DETECTION | STELLAROMICS, INC. (US) | 2025-01-16 | — | — | WO | claimed |
| EP-3825400-B1 | MULTIMERIC CODING NUCLEIC ACID AND USES THEREOF | TRANSLATE BIO INC (US) | 2024-12-25 | — | — | EP | claimed |
| CN-119173636-A | RNA molecules | 帝国理工学院创新有限公司 | 2024-12-20 | — | — | CN | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-20030119764-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-26 | — | — | US | claimed |
| EP-1165585-A1 | CLEAVAGE OF NUCLEIC ACID FROM SOLID SUPPORTS | Goldsborough, Andrew (FR) | 2002-01-02 | — | — | EP | claimed |
| WO-2000058329-A1 | CLEAVAGE OF NUCLEIC ACID FROM SOLID SUPPORTS | GOLDSBOROUGH, ANDREW (FR) | 2000-10-05 | — | — | WO | claimed |
| EP-0948256-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1999-10-13 | — | — | EP | claimed |
| WO-1998018324-A1 | INDUCTION OF VIRAL MUTATION BY INCORPORATION OF MISCODING RIBONUCLEOSIDE ANALOGS INTO VIRAL RNA | THE UNIVERSITY OF WASHINGTON (US) | 1998-05-07 | — | — | WO | claimed |
| CN-1148811-A | Compound having antihypertensive, cardioprotective, anti-ischemic and antilipolytic functions | RHONE POULENC RORER PHARMA (US) | 1997-04-30 | — | — | CN | claimed |
| CN-1147815-A | Adenosine derivatives | SANDOZ LTD (CH) | 1997-04-16 | — | — | CN | claimed |
| EP-0526866-A1 | The use of adenosine compounds for the preparation in the treatment of ischaemia | BIORESEARCH S.p.A. (IT) | 1993-02-10 | — | — | EP | claimed |